Non-small-cell lung cancer is the leading cause of cancer-related death worldwide 1 . Chemotherapies such as the topoisomerase II (TopoII) inhibitor etoposide effectively reduce disease in a minority of patients with this cancer 2, 3 ; therefore, alternative drug targets, including epigenetic enzymes, are under consideration for therapeutic intervention 4 . A promising potential epigenetic target is the methyltransferase EZH2, which in the context of the polycomb repressive complex 2 (PRC2) is well known to tri-methylate histone H3 at lysine 27 (H3K27me3) and elicit gene silencing 5 . Here we demonstrate that EZH2 inhibition has differential effects on the TopoII inhibitor response of non-small-cell lung cancers in vitro and in vivo. EGFR and BRG1 mutations are genetic biomarkers that predict enhanced sensitivity to TopoII inhibitor in response to EZH2 inhibition. BRG1 loss-of-function mutant tumours respond to EZH2 inhibition with increased S phase, anaphase bridging, apoptosis and TopoII inhibitor sensitivity. Conversely, EGFR and BRG1 wild-type tumours upregulate BRG1 in response to EZH2 inhibition and ultimately become more resistant to TopoII inhibitor. EGFR gain-of-function mutant tumours are also sensitive to dual EZH2 inhibition and TopoII inhibitor, because of genetic antagonism between EGFR and BRG1. These findings suggest an opportunity for precision medicine in the genetically complex disease of non-small-cell lung cancer.
To validate that EZH2 is an important target for non-small-cell lung cancer (NSCLC), we generated a 116-gene lung cancer EZH2 coexpression gene signature (Supplementary Table 1 ). This signature had predictive power for cancer progression using the Director's Challenge data set of 416 human lung adenocarcinomas 6 , partly because of stratification of later-stage tumours to the EZH2 high group (Extended Data Fig. 1a ). To control for this covariate, exclusively stage 1 and moderately differentiated tumours were examined, confirming that the signature could robustly further stratify patients into risk groups (Fig. 1a ). Gene ontology analysis revealed that the EZH2 co-expression signature was highly enriched for cell cycle, DNA synthesis and DNA repair genes (Supplementary Table 2 ). One of the genes highly co-expressed with EZH2 in primary tumours was topoisomerase 2A (TOP2A), which encodes the TopoII helicase targeted by etoposide.
To test EZH2 inhibition as a therapy for NSCLC, EZH2 expression was stably knocked down with one of two different small hairpins in a panel of NSCLC cell lines. Western blot confirmed that EZH2 protein and catalytic mark, H3K27me3, were decreased in each transduced cell line and could be rescued by EZH2 expression from a second lentivirus ( Fig. 1b and Extended Data Fig. 1b ). We then determined etoposide half-maximum inhibitory concentration (IC 50 ) at 4 days. Of the seven lines, HCC15, A549, H157 and PC9, termed 'sensitized' lines, had lower etoposide IC 50 when EZH2 was knocked down. Conversely, H460, H23 and Sw1573 cell lines, termed 'protected' lines, had higher etoposide IC 50 as shEZH2 lines (Fig. 1c ). Rescue of EZH2 levels completely abrogated the change in etoposide IC 50 driven by the 39 untranslated region (UTR) targeting hairpin (A549 and Sw1573; Fig. 1c , grey bars). The sensitized and protected phenotypes were not due to differential degrees of EZH2 knockdown (Extended Data Fig. 1b, c) .
Next, we used pharmacological EZH2 inhibition via the S-adenosylhomocystein hydrolase inhibitor, DZNep, which causes proteosomal degradation of PRC2 components including EZH2 (refs 7, 8) and the specific EZH2 methyltransferase inhibitor, GSK126 (ref. 9 ). Western blot confirmed that 4 days of 1 mM DZNep effectively reduced EZH2 protein and H3K27me3, and 10 mM GSK126 for 4 days or 2 mM GSK126 for 9 days caused a decrease in H3K27me3 levels yet EZH2 remained unchanged ( Fig. 1d and Extended Data Fig. 2a ). Fourteen of 26 NSCLC cell lines were more sensitive to 4-day etoposide in the presence of 1 mM DZNep, while the other lines were less sensitive to the chemotherapy in the presence of DZNep ( Fig. 1e and Extended Data Fig. 2b ). For the sensitized lines, pretreatment with 2 mM GSK126 for 9 days sensitized the lines to 4-day etoposide with continued GSK126 treatment (14 days total). For the protected lines, 10 mM of GSK126 for 4 days best recapitulated the etoposide protection caused by DZNep and shEZH2 ( Fig. 1e and Extended Data Fig. 2c ). IC 50 shift results were validated with the Chou-Talalay combination index 10 , demonstrating strong synergism (combination index , 0.48) between DZNep and etoposide as well as synergism (combination index , 0.64) between GSK126 and etoposide ( Fig. 1f and Supplementary Table 3 ). The combination index assay also confirmed drug antagonism (combination index . 1) in the protected lines.
We examined the mutational annotation available for the NSCLC lines and found that 12 of 14 sensitized cell lines harboured inactivating mutations in BRG1 (SMARCA4) or activating mutations in EGFR, while 10 of 12 protected cell lines were wild type (WT) for the two genes (Supplementary Table 4 and Extended Data Fig. 2c ; Fisher's exact test, P 5 0.001). Cell lines segregated into the same genotype-specific protected and sensitized classes when a different TopoII inhibitor, doxorubicin 11 , was combined with DZNep (Extended Data Fig. 2d ).
To determine whether the protected and sensitized phenotypes could be observed in vivo, we treated xenograft-bearing mice with etoposide and EZH2 inhibition (EZH2i). For the sensitized BRG1 mutant cell line H157, early treatment with dual etoposide and DZNep therapy prevented tumours from forming in four out of six mice, proving more efficacious than etoposide or DZNep alone ( Fig. 2a and Extended Data Fig. 3a, b ). In contrast, the protected H23 xenografts that received early dual therapy grew significantly larger than those treated with either DZNep or etoposide alone ( Fig. 2b and Extended Data Fig. 3b ). Furthermore, in mice with established EGFR-driven PC9 xenografts, the combination of GSK126 and etoposide prevented tumour growth ( Fig. 2c ).
Next, mouse models of lung cancer predicted to be sensitized (EGFR T790M;L858R transgenic; EGFR hereafter 12 ) or protected (Kras G12D/1 ; p53 D/D ; Kras/p53 hereafter 13 ) tumour types were treated with DZNep and etoposide. The Kras/p53 model, WT for Brg1 and Egfr, represents a predicted 'protected' cancer, whereas the EGFR model, driven by oncogenic EGFR, represents a predicted 'sensitized' cancer. Etoposide, DZNep, or combination therapy was then administered to randomized cohorts of mice with radiographically documented lung masses for 4 weeks (Fig. 2d ). Marked tumour regression in the EGFR model was observed in response to 4 weeks of dual etoposide and DZNep treatment, while mice in the other treatment arms showed continued tumour growth ( Fig. 2e and Extended Data Fig. 4a ). In striking contrast, the Kras/p53 tumours proceeded to grow despite dual treatment ( Fig. 2f ). DZNep efficacy was confirmed by EZH2 immunohistochemistry for both models (Extended Data Fig. 4b, c ).
To address the mechanism through which EZH2i changed sensitivity to TopoII inhibitor (TopoIIi), we considered the physical interaction between BRG1 and TopoII that allows for increased TopoII function 14 . Because BRG1 and EZH2 are known to be genetically antagonistic 15 , we hypothesized that protected cell lines upregulated BRG1 in response to EZH2i and thereby had increased TopoII function. BRG1 transcript measured by quantitative PCR with reverse transcription (RT-qPCR) was reproducibly increased by DZNep treatment, although BRG1 levels were not significantly different when the cells were treated with GSK126 ( Fig. 3a) . To assess the function of BRG1-containing BAF complexes we quantified anaphase bridges, which are known to indicate a failure of TopoII to decatenate DNA before mitosis and can be attributable to BAF complex dysfunction (Extended Data Fig. 5a ). DZNep or GSK126 treatment increased anaphase bridges in BRG1 mutant cell lines and decreased anaphase bridges in WT cells ( Fig. 3b and Extended Data Fig. 5b ). EGFR mutant cells, despite BRG1 upregulation, also had increased anaphase bridging with DZNep or GSK126 treatment and showed high levels of EGFR in dividing cells (Extended Data Fig. 5c ).
We next examined cell cycle and apoptosis dynamics of the lines. While the protected lines showed no difference in apoptotic levels in etoposide compared with dual-treated cultures, the sensitized lines had significantly higher apoptotic fractions in dual-treated cultures than in cultures treated with etoposide as a single agent ( Fig. 3c ). Furthermore, protected etoposide-treated lines had an average of 13.5% fewer cells in Either the H157 (a) or the H23 (b) cell line was injected into the flanks of Nude mice and tumours were allowed to form. On day 12, mice were randomly segregated into cohorts that received either placebo, DZNep, etoposide or dual therapy for 2 weeks, and average tumour size 6 s.e.m. were plotted (n for tumours/mice in each arm indicated on graphs; *P 5 0.002, **P 5 0.0005 dual versus etoposide). c, The PC9 cell line was injected into the flanks of Nude mice and tumours were allowed to grow to 70 mm 3 . Mice were then treated with etoposide, GSK126, dual therapy or gefitinib (as a positive control) for 2 weeks, and average tumour size 6 s.e.m. were plotted (n indicated on legend, mice with one tumour each; P , 0.008 for dual versus etoposide or GSK126 alone Challenge samples were hierarchically clustered into two risk groups using the EZH2 co-expression signature (Supplementary Table 1 ). The Kaplan-Meier curves only for stage 1 (n 5 94) or only for moderately differentiated tumours (n 5 142) to 6 years after diagnosis are shown. b, Western blot for EZH2 and H3K27me3 on indicated transduced lines; total histone H3 is shown as loading control. CR indicates a coding region targeting hairpin. c, Fold change 6 s.e.m. in etoposide IC 50 between transduced lines (n 5 3 biological replicates for HCC15, A549, PC9, H23 and Sw1573, n 5 4 biological replicates for HCC15 and H460, rescues n 5 3 biological replicates; *P , 0.04, **P , 0.01). d, Western blot for EZH2 and H3K27me3 on lines treated with indicated drugs. e, Fold change 6 s.e.m. in etoposide IC 50 between vehicle-treated and drugtreated lines (n 5 3 biological replicates for all except n 5 4 biological replicates for H157 1 DZNep; *P , 0.04, **P , 0.01). f, Average Chou-Talalay combination index values 6 s.e.m. (also see Supplementary Table 3 ) for fractions affected equivalent to IC 25 -IC 75 (n 5 3 biological replicates).
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G2015 Macmillan Publishers Limited. All rights reserved S phase in response to DZNep or shEZH2 compared with treatment with etoposide alone, suggesting these lines undergo cell cycle arrest sparing them from apoptosis. In contrast, sensitized etoposide-treated lines had an average of 16.5% more cells in S phase in response to DZNep or shEZH2 ( Fig. 3d and Extended Data Fig. 6a ), suggesting that apoptosis of G2/M cells that could not repair anaphase bridges contributed to enrichment for S phase. While the links between EZH2, BRG1 and TopoII explained increased sensitivity of BRG1 mutants to TopoIIi, it was still unclear why EGFR mutants behaved similarly. In our panel of cell lines, 30% had a BRG1 mutation and 23% had an EGFR mutation; however, none had both BRG1 and EGFR mutations ( Supplementary Table 4 and Extended Data Fig. 7a ; Fisher's exact test P 5 0.005). Similarly, in a panel of 412 sequenced primary adenocarcinomas 16, 17 , 65 (15.7%) had mutation in EGFR, while 33 (8%) had mutations in BRG1. With these allele frequencies, 1.25% of the tumour samples were expected to have both BRG1 and EGFR mutations; however, only 1 (0.2%) was observed (Fisher's exact test, P 5 0.019, EGFR R574L). The negative correlation of BRG1 and EGFR mutations suggests that they may be functionally redundant-BRG1 loss may be permissive for high EGFR expression. Supporting this idea, a strong negative correlation was found between EGFR and BRG1 expression in the Director's Challenge data set ( Fig. 4a ). When comparing gene expression of EGFR and BRG1 mutant cell lines to WT lines, EGFR was the first of 21 shared upregulated genes, overexpressed 3.1-fold in BRG1 mutant cell lines and 3.25-fold in EGFR mutant cell lines (Extended Data Fig. 7b , c and Supplementary Table 5 ).
To understand their genetic relationship better, EGFR and BRG1 expressions were manipulated ( Fig. 4b and Extended Data Fig. 8a ). BRG1 re-expression in the HCC15 lines converted the line from a sensitized to protected phenotype, and the HCC15 shEGFR line was no longer sensitized to etoposide by DZNep ( Fig. 4c ). Similarly, DZNep had no effect on etoposide IC 50 when EGFR was overexpressed or BRG1 was knocked down in H460 cells (Fig. 4c ). These changes in etoposide sensitivity were LETTER RESEARCH consistent with changes in anaphase bridging, apoptosis and S phase accumulation ( Fig. 4d and Extended Data Fig. 8b, c) . The ENCODE database 18 shows a chromatin immunoprecipitation peak for BRG1 upstream of EGFR (Fig. 4e ). HCC15 cells re-expressing BRG1 had lower levels of EGFR by RT-qPCR and immunofluorescence (Fig. 4b, f ). We hypothesized that BRG1-containing BAF complexes bind to the EGFR regulatory element to disrupt EGFR transcription, as observed in other systems 19 . We confirmed the exogenously expressed BRG1 was being incorporated into BAF complexes (Extended Data Fig. 9a) , and then performed chromatin immunoprecipitation assays. BRG1, immunoprecipitated with an antibody recognizing the protein itself or the Flag-tag, was significantly associated with the EGFR regulatory element (Fig. 4g ). This genetic antagonism explains why dividing cells in EGFR-driven cultures may not sufficiently upregulate BRG1, and respond to combined etoposide and EZH2i with increased anaphase bridging as BRG1 mutant cells do (Fig. 4h) .
Our results suggest that dual EZH2i plus TopoIIi represents a treatment option for EGFR mutant tumours, even those that invariably develop resistance to EGFR tyrosine-kinase inhibitors 12 . Furthermore, combination EZH2i plus TopoIIi offers the first specific therapeutic for BRG1 mutant lung cancers. Importantly, the strong antagonism of etoposide and EZH2i warns against using this drug combination for EGFR and BRG1 WT tumours. Also notable is the fact that EZH2i either sensitized to etoposide (synergism) or protected from it (antagonism), but very rarely was additivity observed. We and others 20, 21 have found that BRG1 and EGFR mutations are significantly anti-correlated in NSCLC. Moreover, BRG1 mutant NSCLCs had elevated EGFR levels, raising the possibility that BRG1 mutant tumours represent a subset of patients with WT EGFR that respond to EGFR tyrosine-kinase inhibitor 20, 21 . Unlike Brg1-deficient MEFs 14 , BRG1 mutant lung cancer cells did not exhibit TopoII dysfunction unless EZH2 was inhibited, suggesting a novel connection between EZH2 and TopoII function.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Cell lines. Cell lines used are listed in Supplementary Table 4 . All cell lines were maintained in RPMI 1640 media with 10% fetal bovine serum, 4 mM L-glutamine and penicillin/streptomycin at 37 uC, 5% CO 2 . Cell lines were obtained from the Meyerson laboratory at Dana-Farber Cancer Institute. No mycoplasma was detected in cultures by either routine mycoplasma PCR or perinuclear 49,6-diamidino-2phenylindole (DAPI) staining. Cell line genotypes ( Supplementary Table 4 ) were obtained from published studies 22, 23 , COSMIC database 24 and CCLE database 25 . Vectors. The pLKO.1 EZH2 shRNA construct clones TRCN0000040076 and TRCN0000040073 were purchased from Sigma and the shGFP plasmid 12273 is available on Addgene 26 . Both shBRG1 and the matched empty vector were provided by the Smale laboratory 27 and are available on Addgene, the BRG1 overexpression plasmid 19148 from the Massagué laboratory 28 was purchased through Addgene, and the shEGFR and EGFR WT overexpression constructs were provided by the Jänne laboratory 29 . The EZH2 overexpression construct was derived by cloning human EZH2 cDNA into pLenti7.3/V5-DEST (Invitrogen). Lentivirus was packaged in HEK293T cells using established protocols 30 , and retrovirus was packaged in PlatE cells again using established protocols 31 . Cell lines were infected with viralcontaining supernatant containing 6 mg ml 21 polybrene (Sigma) for a period of 10-18 h. Infected cultures were selected with 1 mg ml 21 puromycin (all sh constructs and EGFR overexpression, SIMGA), 200 mg ml 21 hygromycin (BRG1 overexpression, Invitrogen), or by flow cytometry for GFP (EZH2 overexpression) 5 days after infection.
Small hairpin sequences: GFP: GCCC(GCAAGCTGACCCTGAAGTTCAT)T CAAGAG(ATGAACTTCAGGGTCAGCTTGC)TTTT; EZH2 coding region: C CGG(CGGAAATCTTAAACCAAGAAT)CTCGAG(ATTCTTGGTTTAAGAT TTCCG)TTTTT; EZH2 39 UTR: CCGG(TATTGCCTTCTCACCAGCTGC)CT CGAG(GCAGCTGGTGAGAAGGCAATA)TTTTT; EGFR: CCGG(GCTGAG AATGTGGAATACCTA)CTCGAG(TAGGTATTCCACATTCTCAGC)TTTTT; BRG1: TTTG(TGGATAAGCAGCACAAGATT)TCAAGAG(AATCTTCTGCT GCTTCTCCA)TTTTT. Drugs. Etoposide and doxorubicin (Sigma) were diluted to a stock of 100 mM in dimethyl sulphoxide (DMSO) for all cell culture experiments. DZNep was a gift from V.E.M. and was diluted in DMSO to a stock of 10 mM. GSK126 was purchased from Xcess Bio as a 10 mM stock in DMSO. All stocks were diluted in DMSO to 1,0003 concentration before addition into media at 23 concentration and final dilution onto plated cells 1:1. Cytotox assays. Cell lines were dissociated, counted and plated at 5,000 cells per well in flat-bottomed opaque tissue-culture-treated 96-well plates (CytoOne). Edge wells were filled with PBS. The following day, 23 drug diluted in media was added to each well such that the well then contained 100 ml media with 13 drug concentration at the following doses: etoposide, 0, 0.1, 1, 3, 5, 7, 10, 50, 100, 500 mM; or doxorubicin, 0, 0.01, 0.1, 0.5, 1, 3, 5, 7, 10, 50 mM; with or without additional 1 mM DZNep, 10 mM GSK126 or a continuation of 2 mM GSK126 from a 9-day 2 mM GSK126 pretreated culture. After 4 days, CellTiter-Glo (Promega) was added and luminescence was read on a BioTec plate reader to determine relative cell number in each well. Data were averaged for triplicate or quadruplicate technical replicates and normalized to the untreated wells, and whole runs (vehicle and EZH2i) were excluded if vehicle-treated wells did not reach the threshold luminescence of 3,000. Results from independent biological replicate experiments were input into Graph-Pad Prism software to extrapolate the IC 50 and s.e.m. of IC 50 for a given cell line using the nonlinear regression analysis of log(inhibitor) versus normalized response with a variable slope. For 1 mM DZNep for 4 days with etoposide, n 5 3 biological replicates for H1975, H2030, HCC4006, A549, HCC2450, Calu1, H1650, H522, H2126, H1299, HCC15, H322, H2009, HCC95, H520, H460, Calu3, H2122, H23 and H3255; n 5 4 biological replicates for PC9, H157, HCC827, Sw1573, Calu6 and H441. For both 2 mM GSK126 pretreated for 9 days and continued for 4 days with etoposide, and 10 mM GSK126 treated for 4 days with etoposide, n 5 3 biological replicates. The log(IC 50 ) values were compared using GraphPad Prism software, and P values reported are the sum-of-squares F statistics. For graphs, log(IC 50 ) of vehicle control cells was subtracted from log(IC 50 ) of EZH2i-treated cells and multiplied by ten to be depicted as log fold change 3 10. Errors were estimated by calculating possible upper and lower bounds of log fold changes based on GraphPad reported s.e.m. for each log(IC 50 ) calculated.
For Chou-Talalay combination index assays 10 , doses for etoposide, DZNep or GSK126 were 0, 0.1, 0.5, 1, 3, 5, 7, 10, 30, 50 mM and 1:1 combinations of etoposide and DZNep or etoposide and GSK126. Survival percentages for three independent biological replicate experiments were averaged and input into CompuSyn software to extrapolate combination index values. Any drug dose with mean survival over 100% was excluded because the CompuSyn software did not allow for values over 1. In addition, visual inspection led us to remove the highest doses of GSK126 from the analysis for every cell line, as suggested in refs 32 and 33, leading to much better matching of the data points to the median effect plot. Notably, removal of these data points both increased synergy seen in the sensitized lines and increased antagonism seen in H460 and Sw1573 lines. Flow cytometry. For 7AAD-cell cycle analysis, cell lines were plated at 1.5 3 10 6 cells per 10 cm plate and treated with drug for 4 days. Cells were then dissociated, fixed with 100% ice cold ethanol for at least 2 h, incubated for 30 min with 1 mg ml 21 DNase-free RNase A (Thermo) and resuspended in 20 mg ml 21 7-aminoactinomycin D (7AAD; Invitrogen). Thirty thousand events were collected on the BD Fortessa, analysed with ModFit LT software and the results were averaged for three or four biological replicates (n indicated in legend).
For Annexin V/7AAD apoptosis analysis, cell lines were plated at 5 3 10 4 cells per well of a six-well plate and treated with drug for 3 days. Supernatant was retained and added to trypsinized suspensions of adherent cells. Cells were stained with Annexin V-FITC (BD Biosciences) according to the manufacturer's instructions, and resuspended with 1 mg ml 21 7AAD before analysis on BD Fortessa. For sensitized lines 2 mM GSK126 pretreated for 9 days and continued for 3 days with etoposide was used, while for protected line 10 mM GSK126 treated for 3 days with etoposide was used. Data were analysed with FlowJo (Treestar) software and the percentages of Annexin V 1 /7AAD 2 cells were averaged for four biological replicate experiments. Quantitative RT-PCR. RNA from treated cell lines was extracted using Absolutely RNA kits (Agilent) and cDNA was made using the SuperScript III kit (Invitrogen). Relative gene expression was assayed with Sybr green on the StepOnePlus realtime PCR system (Applied Biosystems). Relative expression was calculated by using threshold cycle (C t ) values: gene of interest(C t, reference 2 C t, experimental ) 2 CYPA(C t, reference 2 C t, experimental ) and graphs potted on the log 2 scale or converted to linear scale. Statistics were performed on log 2 data. For all experiments, the reference sample was a matched vehicle-treated or control transduced cell line.
Primer sequences: CYPA: F TCATCTGCACTGCCAAGACTG R CATGCCT TCTTTCACTTTGCC; EZH2: F AGGAGTTTGCTGCTGCTCTC R CCGAGA ATTTGCTTCAGAGG; BRG1: F AGCGATGACGTCTCTGAGGT R GTACAG GGACACCAGCCACT; EGFR: F TAACAAGCTCACGCAGTTGG R GTTGAG GGCAATGAGGACAT. Xenograft experiments. For DZNep experiments, H157 or H23 cells were dissociated into single cells, counted and resuspended at 1 3 10 6 cells per 250 ml of 1:1 media/matrigel (BD). Eight-to 16-week-old female Foxn1 nu /Foxn1 nu (Nude) mice (Harlan) were injected subcutaneously with 1 3 10 6 cells in two to four spots on flanks. Etoposide and DZNep were administered from day 12 to day 17 after injections; etoposide: 20 mg/kg/d intraperitoneally in corn oil once per day for 5 consecutive days; DZNep 2 mg/kg/d intraperitoneally in corn oil twice per week for 1 week, or 1 mg/kg/d intraperitoneally in corn oil twice per week for 2 weeks. Tumour growth was measured every other day by calliper in a non-blinded fashion. For GSK126 experiments, PC9 cells were dissociated into single cells, counted and resuspended at 1 3 10 6 cells per 250 ml of 1:1 media/matrigel (BD). Eight-to 16-weekold female Foxn1 nu /Foxn1 nu mice (Harlan) were injected subcutaneously with 1 3 10 6 cells in one spot on left flank. Tumours were allowed to grow for 23 days to a mean size of 70 mm 3 . Mice were then randomized into groups that received etoposide, GSK126, both etoposide and GSK126, gefitinib or vehicle: etoposide 10 mg/kg/d intraperitoneally in corn oil three times a week, GSK126 300 mg/kg/d intraperitoneally in 1:1 v/v GSK126/Captisol mixture resuspended in sterile water with acetic acid to pH 4.8, gefitinib (LC Laboratories) 150mg/kg/d in 1% Tween-80 (Sigma). All mouse experiments were approved by the BCH Animal Care and Use Committee and by the Dana-Farber Cancer Institute Institutional Animal Care and Use Committee, both accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, and were performed in accordance with relevant institutional and national guidelines and regulations. Generation of the EZH2 co-expression gene signature. We used Oncomine 34 to query the top 20 genes co-expressed with EZH2 in all data sets containing human non-small-cell lung cancer samples and co-expression data 6, [35] [36] [37] [38] [39] [40] [41] . We chose 20 probes for examination from each study, to yield a list between 100 and 200 genes, which allowed for robust hierarchal clustering of samples similar to that in previous studies. Of the 180 probes, 64 were redundant, leading to a list of 116 genes highly co-expressed with EZH2 ( Supplementary Table 1 ). Because these data sets were from various microarray platforms, the gene list was then used to generate a probe list for the 116 genes corresponding to probes on the U133A Affymetrix array using the batch query function on the NetAffx website (http://www.affymetrix. com/analysis/index.affx). Gene ontology analysis was performed on the EZH2 co-expression signature with dChip software (http://www.hsph.harvard.edu/cli/ complab/dchip/). Microarray analysis. All array data are publically available on Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) and correspond to array files available from GSE4824 (ref. 42) for all lines except A549, H522 and PC9, GSE5457 for A549 (two replicates), GSE5720 (ref. 43 ) for H522 and an additional A549, GSE7670 (ref. 44 ) for an additional H1299, GSE10089 (ref. 45 ) for PC9 and H1650, and LETTER RESEARCH GSE31625 (ref. 46) for an additional PC9. Arrays were chosen based on availability in September 2012. Arrays were analysed using R/Bioconductor (http://www.bio conductor.org/). Raw CEL files from U133A Affymetrix arrays were processed using the robust multiarray average algorithm 47 . To identify genes correlating with the phenotypic groups, we used limma 48 to fit a statistical linear model to the data and then tested for differential gene expression in the three groups using the vennSelect package-WT: H460, H441, H2122, H2009, Calu6, HCC95; EGFR mutant: H1650, HCC827, HCC4006, H1975, H3255, PC9; BRG1 mutant: A549, H1299, H157, H2126, H522, HCC15. Results were adjusted for multiple testing using the Benjamini and Hochberg method 49 , and significance was determined using a false-discovery-rate cutoff of less than 5%. For correlation between EGFR and BRG1 expression in the Director's Challenge data set, the arrays were processed using RMA and limma as described above. Tumours with a robust multiarray average normalized expression of more than 2,000 for EGFR or 575 for BRG1 were plotted and correlation was assessed-because these data were nonparametric, Spearman's correlation coefficient was used. Using this same method of selecting for highest-expressing tumours, we could visualize positive correlations between EZH2 and other EZH2 co-expression gene signature members (data not shown). Kaplan-Meier analysis. Raw gene expression data from the Director's Challenge human lung adenocarcinoma samples 6 were obtained (https://caintegrator.nci. nih.gov/caintegrator/). Probe intensities from the Affymetrix U133A platform used in these studies were normalized and modelled using dChip software 50 (http://www. hsph.harvard.edu/cli/complab/dchip/). Kaplan-Meier survival analyses were implemented after the samples were hierarchically clustered using centroid linkage, rank correlation and gene peaking time into two risk groups using the EZH2 coexpression gene signature. Survival differences between the two risk groups were assessed using the Mantel-Haenszel log-rank test. The large area between the two risk groups and its associated small P value from the Mantel-Haenszel log-rank test implicate a robust survival classification model. Statistical analysis. No statistical methods were used to predetermine sample size. Except where indicated, a two-tailed Student's t-test with equal variance was used to compare measurements between two conditions with at least three biological replicates per condition. Normal distribution was checked with the Kolmogorov-Smirnov test; data that failed the test at a 5 0.05 were considered normally distributed. If the data were non-parametric, then a two-tailed Mann-Whitney U-test was used instead of a t-test to assess the P value. Unless noted otherwise, pooled data are represented by the mean and standard error. P values are indicated in figure legends, and P values less than 0.05 were considered significant. Western blot. Whole-cell extracts were made in RIPA buffer (0.5% Deoxycholate, 1% IGEPAL-CA630, 0.1% sodium dodecyl sulphate, 150 mM NaCl, 50 mM Tris-8.1), lysates were cleared by centrifugation, and protein concentrations were quantified with the Pierce BCA Protein Assay Kit (Thermo). For western blotting, 25 mg of protein extract per sample was denatured with heat and reducing agents, separated on a 4-12% acrylamide gel (BioRad) and transferred to nitrocellulose (GE Healthcare). Antibodies used for western blotting were as follows: EZH2 (clone D2C9; Cell Signaling; 1:200), Histone H3 (polyclonal; AbCAM ab1791; 1:2,000) and H3K27me3 (polyclonal; Millipore 07-449; 1:1,000), all incubated overnight at 4 uC. All antibodies have detailed species validation available online from vendors. Secondary antibody, anti-rabbit-HRP (Santa Cruz sc-2313; 1:10,000), was incubated for 1 h at room temperature. After washing, chemiluminescence was visualized with Western Lightning Plus-ECL (PerkinElmer) and exposure onto KODAK BioMax XAR film. Immunoprecipitation. Cultured cells (10 3 10 6 per line) were collected by trypsinization and pelleting, followed by PBS wash and pelleting. On ice, cell pellets were resuspended in 750 ml hypotonic buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 ) and incubated for 15 min. NP-40 (10%, 37.5 ml) was added to each tube followed by vortexing for 10 s and centrifugation for 10 min at 650g at 4 uC. Nuclear pellets were then resuspended in RIPA buffer for 30 min on ice with vortexing, lysates were cleared by centrifugation and protein concentrations were quantified with the Pierce BCA Protein Assay Kit (Thermo). Antibodies directed against Flag (M2; Sigma; 1:50), BAF155 (R-18; Santa Cruz; 1:50) or ARID1a (PSG3; Santa Cruz; 1:10) were incubated with 300 mg of each nuclear extract with 1:1 Protein A and Protein G agarose beads (GE Healthcare) rotating at 4 uC overnight. All antibodies had detailed species validation available online from vendors. Beads were washed three times in 1 ml RIPA buffer with the second wash being rotated at 4 uC for 30 min, then resuspended in approximately 35 ml 13 reducing buffer and boiled for 5 min before loading 10 ml per lane. Proteins were separated on a 4-12% acrylamide gel (BioRad) and transferred to nitrocellulose (GE Healthcare). Antibodies for western blotting were as follows: Flag (M2; Sigma; 1:1,000), BAF155 (R-18; Santa Cruz; 1:1,000) and ARID1a (polyclonal; Bethyl Laboratories A310-040A; 1:1,000). Secondary antibody, anti-rabbit-HRP (Santa Cruz sc-2313; 1:10,000), antimouse-HRP (Santa Cruz sc-2314; 1:10,000) or anti-goat-HRP (Santa Cruz sc-2020; 1:10,000) were incubated for 1 h at room temperature. After washing, chemilumin-escence was visualized with Western Lightning Plus-ECL (PerkinElmer) and exposure onto KODAK BioMax XAR film. Anaphase bridge analysis. To quantify anaphase bridges, cells were grown on fourwell cultures slides (Lab Tek II). Adherent cells were fixed with 4% paraformaldehyde for 20 min, washed and stained with Vectashield with DAPI (Vector Labs). Images were taken of each anaphase structure, and the number of anaphases with bridges over the total number of anaphases (between 11 and 34 total anaphases per well of a four-well chamber slide) was recorded for each of three or more independent biological replicate experiments in a blinded fashion. Exact biological replicates n for Fig. 3b Immunofluorescence. Cells were fixed in 4% paraformaldehyde and permeabilized with 10% Normal Donkey Serum (Jackson Immunoresearch), 0.25% Triton-X (Sigma), both in PBS. Primary antibodies, Brg1 (clone G-7, Santa Cruz) and EGFR (polyclonal; Cell Signaling 2232) were incubated overnight at 1:100 dilution in PBS, 10% Normal Donkey Serum. All antibodies had detailed species validation available online from vendors. Slides were washed three times and secondary antibodies, anti-mouse-AlexaFluor594 and anti-rabbit-AlexaFluor488 (Invitrogen) were incubated at 1:500 for 1 h. After washing, cover slips were mounted with Vectashield with DAPI (Vector Labs). Imaging was performed with a Nikon 90i camera and NIS-Elements software, and processed with NIS-Elements and Adobe Photoshop. All treatment groups were imaged with the same exposure time and equivalent processing. Images were chosen to highlight the difference between BRG1 high interphase cells and EGFR high dividing cells in EZH2i-treated PC9 cultures. Treatment and magnetic resonance imaging of endogenous mouse models. Doxycycline-inducible EGFR T790M;L858R transgenic mice 12 and Lox-Stop-Lox-Kras G12D/1 ;p53 fl/fl (Kras G12D/1 ;p53 D/D ) 13,51 mice were maintained on a mixed background, housed in a pathogen-free environment at the Harvard School of Public Health and handled in strict accordance with Good Animal Practice as defined by the Office of Laboratory Animal Welfare. All animal work was done with Dana-Farber Cancer Institute Institutional Animal Care and Use Committee approval. Cohorts of male and female EGFR T790M;L858R ;CCSP-rtTA were put on a doxycycline diet at 6 weeks of age to induce the expression of mutant EGFR, while male and female Kras G12D/1 ;p53 D/D mice received intranasal adeno-Cre between 6 and 8 weeks of age. Mice were evaluated by magnetic resonance imaging 12-16 weeks after doxycycline diet or adeno-Cre infection to document and quantify the lung cancer burden before being randomized to various treatment study cohorts. Treated mice in all cohorts had similar initial tumour burden. Tumour-bearing mice were randomized into cohorts treated either with vehicle (corn oil), etoposide 10 mg/kg intraperitoneally three times a week for 4 weeks, DZNep 4 mg/kg intraperitoneally twice a week for 4 weeks or both etoposide and DZNep. The mice were imaged by magnetic resonance imaging every 2 weeks to determine the reduction in tumour volume during the respective treatments as described previously in a non-blinded fashion 12 . The tumour burden volume and quantification were reconstructed on three-dimensional slicer software (http://www.slicer.org). Immunohistochemistry was performed as described with anti-EZH2 (clone D2C9; Cell Signaling) or anti-pEGFR (Y1068; clone D7A5; Cell Signaling) and developed using Vectastain Elite ABC kit (Vector Labs). Imaging was performed with a Nikon 90i camera and NIS-Elements software, and processed with NIS-Elements and Adobe Photoshop. Chromatin immunoprecipitation. Five million cells were fixed in 1% formaldehyde for 10 min before addition of glycine to a concentration of 1 mM. Cells were pelleted, washed and resuspended in chromatin immunoprecipitation sonication buffer (1% Triton X-100, 0.1% deoxycholate, 50 mM Tris 8.1, 150 mM NaCl, 5 mM EDTA) containing protease and phosphastase inhibitors (Roche). Samples were sonicated for a total of 3 min in 30 s cycles with 1 min breaks. Sonicated samples were centrifuged for 15 min to clear the lysates, and resulting whole-cell extracts were used for pull-downs. Antibodies directed against GFP (Ab-1; Neomarkers), BRG1 (G-7; Santa Cruz) and Flag (M2; Sigma) were incubated with equal proportions of whole-cell extracts at 1:30 dilution overnight, rotating at 4 uC. Protein A and Protein G agarose beads (1:1; GE Healthcare) were added and incubated for 2 h at 4 uC. Beads were then pelleted and washed with high salt wash buffer (1% Triton X-100, 0.1% deoxycholate, 50 mM Tris-8.1, 500 mM NaCl, 5 mM EDTA), followed by LiCl immune complex buffer (250 mM LiCl, 0.5% IGEPAL-CA630, 0.5% deoxycholate, 10 mM Tris-8.1, 1 mM EDTA) and TE (10 mM Tris-8.1, 1 mM EDTA) before suspension in elution buffer (1% SDS, 0.1 M NaHCO2, 0.01 mg ml 21 salmon sperm DNA (GE Healthcare)). Crosslinks were reversed at 65 uC overnight, beads were pelleted, and resulting supernatant was incubated with 0.4 mg ml 21 Proteinase K (Sigma) for Extended Data Figure 2 | Pharmacological inhibition of EZH2 changes response of cells to TopoII inhibitors. a, Western blot for EZH2 and H3K27me3 was performed on whole-cell extracts after administration of 1 mM DZNep for 4 days, 10 mM GSK126 for 4 days, 2 mM GSK126 for 9 days, or vehicle. Total histone H3 is shown as a loading control. b, The fold change in etoposide IC 50 6 s.e.m. in response to DZNep is plotted (n 5 3 biological replicates for H1975, H2030, HCC4006, A549, HCC2450, Calu1, H1650, H522, H2126, H1299, HCC15, H322, H2009, HCC95, H520, H460, Calu3, H2122, H23 and H3255; n 5 4 biological replicates for PC9, H157, HCC827, Sw1573, Calu6 and H441; *P , 0.02). Cell lines with mutations in BRG1 or EGFR are indicated. Note that the H23 cell line has a very late coding region mutation in BRG1 (K1533N) and is predicted to produce functional protein 22 , consistent with its protected phenotype in our assays. c, Fold change 6 s.e.m. between vehicle-treated and indicated EZH2i-treated lines for etoposide IC 50 is plotted (n 5 3 biological replicates; *P , 0.03, **P , 0.01). d, Fold change in doxorubicin IC 50 in response to DZNep (n 5 2 biological replicates). 
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